GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B7611 VPC 230191 CitationSummary: S1P1/S1P3 receptor antagonist
- B7617 Prostaglandin F2αSummary: Prostaglandin E2 and F2α receptor agonist
- B7631 [D-Trp8]-γ-MSHSummary: melanocortin 3 (MC3) receptor agonist
- B7638 Pamoic acid disodium saltSummary: A GPR35 agonist
- B7639 TC 14012Summary: CXCR4 antagonist and ACKR3 (CXCR7) agonist
- B7647 FC 131Summary: CXCR4 antagonist
- B7649 PSB 1114Summary: P2Y2 receptor agonist
- B7680 (+)-FluprostenolSummary: Prostaglandin F2α (FP) receptor agonist
- B7686 3,5-DHBASummary: hydroxycarboxylic acid receptor 1 (HCA1) agonist
- B7693 TC OT 39Summary: oxytocin receptor partial agonist